Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
Recruiting · Phase 2 · NCT07224360
Conditions: Sickle Cell Disease
At a glance
- Research payments reported, 2025
- $4,374
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 63
About the trial
- Sponsor
- CSL Behring
- Tested
- Anumigilimab (biological), Placebo (drug)
- Dates
- Started 2026-02-02; completion 2028-08-15
- Results posted
- Not yet
This is a phase 2a, global, multicenter, randomized, double-blind, placebo-controlled study investigating the safety of anumigilimab administered subcutaneously (SC) at the maximum tolerated dose (MTD) in adult participants with SCD. The primary aim of the study is to assess the safety of anumigilimab in participants with SCD. Participants will be treated for 64 weeks: for 12 weeks in the dose escalation period, where the dose will be escalated to each participant's individual MTD; and for 52 weeks at the MTD in the maintenance period.
From ClinicalTrials.gov, last updated 2026-11-03. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Csl Behring reported $4,374 in research payments for this study in 2025 (40 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Gershwin T. Blyden, M.D. Internal Medicine · Miami, FL
- Sharon M. Pennington, M.D. Pediatric Hematology & Oncology · Flowood, MS
- Kenneth Rivlin Pediatric Hematology & Oncology · New York, NY
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Southern Specialty Research $1,550
- Jacobi Medical Center, NY $1,550
- The Foundation for Sickle Cell Disease $1,274
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.